drugset / Trial / NCT01511432

A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects

NCT01511432

Phase 1 Completed 64 enrolled Vertex Pharmaceuticals Incorporated
RandomizedCrossoverOpen-label

Summary

The purpose of this study is to evaluate the relative bioavailability, safety, and tolerability of 3 new formulations of telaprevir relative to the Incivek 375-mg tablets.

Timeline

Start
2012-01
Primary completion
2012-06
Completion
2012-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Telaprevir Small molecule 1125 mg Oral